These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 15932361)

  • 1. Empirical treatment for the management of patients presenting with uninvestigated reflux symptoms: a prospective study in an Asian primary care population.
    Ho KY; Gwee KA; Khor CJ; Selamat DS; Wai CT; Yeoh KG
    Aliment Pharmacol Ther; 2005 Jun; 21(11):1313-20. PubMed ID: 15932361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study.
    Malfertheiner P; Nocon M; Vieth M; Stolte M; Jaspersen D; Koelz HR; Labenz J; Leodolter A; Lind T; Richter K; Willich SN
    Aliment Pharmacol Ther; 2012 Jan; 35(1):154-64. PubMed ID: 22070159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.
    Armstrong D; Talley NJ; Lauritsen K; Moum B; Lind T; Tunturi-Hihnala H; Venables T; Green J; Bigard MA; Mössner J; Junghard O
    Aliment Pharmacol Ther; 2004 Aug; 20(4):413-21. PubMed ID: 15298635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healing of erosive esophagitis and improvement of symptoms of gastroesophageal reflux disease after esomeprazole treatment in children 12 to 36 months old.
    Tolia V; Gilger MA; Barker PN; Illueca M
    J Pediatr Gastroenterol Nutr; 2010 Nov; 51(5):593-8. PubMed ID: 20706150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole--results from the STARS II study.
    van Zanten SV; Wahlqvist P; Talley NJ; Halling K; Vakil N; Lauritsen K; Flook N; Persson T; Bolling-Sternevald E;
    Aliment Pharmacol Ther; 2011 Oct; 34(7):714-23. PubMed ID: 21848799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management strategy for patients with gastroesophageal reflux disease: a comparison between empirical treatment with esomeprazole and endoscopy-oriented treatment.
    Giannini EG; Zentilin P; Dulbecco P; Vigneri S; Scarlata P; Savarino V
    Am J Gastroenterol; 2008 Feb; 103(2):267-75. PubMed ID: 18289194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between symptom response and esophageal pH level on standard dose of esomeprazole treatment for gastroesophageal reflux disease.
    Peng S; Xiong LS; Xiao YL; Wang AJ; Lin JK; Hu PJ; Chen MH
    Chin Med J (Engl); 2010 Aug; 123(15):2012-7. PubMed ID: 20819534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between oesophageal acid exposure and dyspeptic symptoms in patients with nonerosive reflux disease.
    Sarnelli G; De Giorgi F; Efficie E; Aprea G; Masone S; Savarese MF; Esposito I; Russo L; Cuomo R
    Eur J Gastroenterol Hepatol; 2008 Apr; 20(4):264-8. PubMed ID: 18334868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empiric esomeprazole in the treatment of laryngopharyngeal reflux.
    DelGaudio JM; Waring JP
    Laryngoscope; 2003 Apr; 113(4):598-601. PubMed ID: 12671413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The gain in quality-adjusted life months by switching to esomeprazole in those with continued reflux symptoms in primary care: EncomPASS--a cluster-randomized trial.
    Moayyedi P; Armstrong D; Hunt RH; Lei Y; Bukoski M; White RJ
    Am J Gastroenterol; 2010 Nov; 105(11):2341-6. PubMed ID: 20842110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study.
    Dent J; Vakil N; Jones R; Bytzer P; Schöning U; Halling K; Junghard O; Lind T
    Gut; 2010 Jun; 59(6):714-21. PubMed ID: 20551454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esomeprazole in acute and maintenance treatment of reflux oesophagitis: a multicentre prospective study.
    Atug O; Giral A; Kalayci C; Dolar E; Isitan F; Oguz D; Ovunc O; Ozgur O; Soykan I; Simsek I; Unal S; Yenice N;
    Adv Ther; 2008 Jun; 25(6):552-66. PubMed ID: 18568450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Water load test before and after PPI therapy in patients with gastro-oesophageal reflux disease.
    Battaglia E; Grassini M; Navino M; Niola P; Verna C; Mazzocchi A; Clerici C; Morelli A; Bassotti G
    Dig Liver Dis; 2007 Dec; 39(12):1052-6. PubMed ID: 17913607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised clinical trial: identification of responders to short-term treatment with esomeprazole for dyspepsia in primary care - a randomised, placebo-controlled study.
    Meineche-Schmidt V; Christensen E; Bytzer P
    Aliment Pharmacol Ther; 2011 Jan; 33(1):41-9. PubMed ID: 21083590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial comparing aerosolized swallowed fluticasone to esomeprazole for esophageal eosinophilia.
    Moawad FJ; Veerappan GR; Dias JA; Baker TP; Maydonovitch CL; Wong RK
    Am J Gastroenterol; 2013 Mar; 108(3):366-72. PubMed ID: 23399553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux.
    Reichel O; Dressel H; Wiederänders K; Issing WJ
    Otolaryngol Head Neck Surg; 2008 Sep; 139(3):414-20. PubMed ID: 18722223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled "ENTER" trial.
    van Zanten SV; Armstrong D; Chiba N; Flook N; White RJ; Chakraborty B; Gasco A
    Am J Gastroenterol; 2006 Sep; 101(9):2096-106. PubMed ID: 16817845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
    Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
    Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal change esophagitis: prospective comparison of endoscopic and histological markers between patients with non-erosive reflux disease and normal controls using magnifying endoscopy.
    Kiesslich R; Kanzler S; Vieth M; Moehler M; Neidig J; Thanka Nadar BJ; Schilling D; Burg J; Nafe B; Neurath MF; Galle PR
    Dig Dis; 2004; 22(2):221-7. PubMed ID: 15383765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-probe 24-hour ambulatory pH monitoring for diagnosis of laryngopharyngeal reflux.
    Issing WJ; Karkos PD; Perreas K; Folwaczny C; Reichel O
    J Laryngol Otol; 2004 Nov; 118(11):845-8. PubMed ID: 15638969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.